EUPRAXIA PHARMACEUTICALS INC (EPRX) Stock Analyst Ratings
USA - NASDAQ:EPRX - CA29842P1053 - Common Stock
5.47 USD
-0.21 (-3.7%)
ChartMill assigns a Buy % Consensus number of 84% to EPRX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 8.06. This target is 47.36% above the current price.
EPRX was analyzed by 9 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about EPRX.
In the previous month the buy percentage consensus was at a similar level.
EPRX was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-07-24 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-06-26 | HC Wainwright & Co. | Initiate | Buy |
| 2024-11-14 | Rodman & Renshaw | Initiate | Buy |
EUPRAXIA PHARMACEUTICALS INC / EPRX FAQ
Can you provide the average price target for EUPRAXIA PHARMACEUTICALS INC stock?
9 analysts have analysed EPRX and the average price target is 8.06 USD. This implies a price increase of 47.36% is expected in the next year compared to the current price of 5.47.
How do analysts rate EUPRAXIA PHARMACEUTICALS INC (EPRX)?
The consensus rating for EUPRAXIA PHARMACEUTICALS INC (EPRX) is 84.4444 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed EUPRAXIA PHARMACEUTICALS INC (EPRX)?
The number of analysts covering EUPRAXIA PHARMACEUTICALS INC (EPRX) is 9.